JPH0331166B2 - - Google Patents
Info
- Publication number
- JPH0331166B2 JPH0331166B2 JP58175581A JP17558183A JPH0331166B2 JP H0331166 B2 JPH0331166 B2 JP H0331166B2 JP 58175581 A JP58175581 A JP 58175581A JP 17558183 A JP17558183 A JP 17558183A JP H0331166 B2 JPH0331166 B2 JP H0331166B2
- Authority
- JP
- Japan
- Prior art keywords
- dops
- erythro
- administered
- locomotor activity
- mania
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000005284 excitation Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 206010026749 Mania Diseases 0.000 description 18
- 230000006742 locomotor activity Effects 0.000 description 16
- 239000003814 drug Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 208000001431 Psychomotor Agitation Diseases 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 7
- 229960001252 methamphetamine Drugs 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 206010007776 catatonia Diseases 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 239000003204 tranquilizing agent Substances 0.000 description 5
- 230000002936 tranquilizing effect Effects 0.000 description 5
- QXWYKJLNLSIPIN-YUMQZZPRSA-N (2s,3s)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-YUMQZZPRSA-N 0.000 description 4
- 239000003954 decarboxylase inhibitor Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 229940123736 Decarboxylase inhibitor Drugs 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 3
- 206010070863 Toxicity to various agents Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 3
- 229910052808 lithium carbonate Inorganic materials 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 208000009810 Catatonic Schizophrenia Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000036754 Schizophrenia, catatonic type Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- -1 aromatic amino acid Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- QXWYKJLNLSIPIN-JGVFFNPUSA-N droxidopa Chemical compound OC(=O)[C@@H](N)[C@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-JGVFFNPUSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QXWYKJLNLSIPIN-JAMMHHFISA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid Chemical compound OC(=O)[C@@H](N)C(O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-JAMMHHFISA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- ZCEHOOLYWQBGQO-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-hydroxy-2,2-diphenylacetate;hydron;chloride Chemical compound Cl.C=1C=CC=CC=1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 ZCEHOOLYWQBGQO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000033618 Elevated mood Diseases 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003561 anti-manic effect Effects 0.000 description 1
- 230000001410 anti-tremor Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical compound CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- QXWYKJLNLSIPIN-SFYZADRCSA-N droxidopa Chemical compound OC(=O)[C@H](N)[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-SFYZADRCSA-N 0.000 description 1
- 229960001104 droxidopa Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- 229940042053 methotrimeprazine Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- VXTWEDPZMSVFEF-UHFFFAOYSA-N pheniprazine Chemical compound NNC(C)CC1=CC=CC=C1 VXTWEDPZMSVFEF-UHFFFAOYSA-N 0.000 description 1
- 229950005573 pheniprazine Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯ïŒ¬ãŸãã¯DLâãšãªã¹ãâïŒâïŒïŒïŒïŒ
âãžããããã·ããšãã«ïŒâã»ãªã³ïŒä»¥äžããšãª
ã¹ãâDOPSãšããïŒãŸãã¯ãã®å¡©ãæå¹æåãš
ãã粟ç¥éåè奮æå¶å€ã«é¢ããã 粟ç¥éåã®é床ãªè奮ã¯ãããã€ãã®ç²Ÿç¥ç¥çµ
çŸæ£ã®ç¹åŸŽççç¶ãšããŠçŸãããã®ã§ãããäŸã
ã°èºïŒãã€ïŒç ã®èºç çžã«ãããå Žåãã粟ç¥å
è£ç ãšãã«ãã®ç·åŒµåã«ãããå Žåãªã©ãã®ä»£è¡š
çäŸç€ºãšèšããã åŸã€ãŠãæ¬çºæã¯ç²Ÿç¥éåè奮ãäž»çåãšãã
èºç ã粟ç¥åè£ç ã®ç·åŒµåã«å¯Ÿããçç¶ã®æ¹åã
æ²»çå€ãšããŠã®ãšãªã¹ãâDOPSã®çšéã«ä¿ãã
ã®ã§ããã èºç ã§ã¯çœå¿«æ°åãåºææ§æ°åãæç¶ãããã
é«æããæ°åãããã¯èŠ³å¿µå¥éžãèªæææ ã®äº¢é²
ãèªãããããããããã®ç²Ÿç¥é«æã¯å ã®ç²Ÿç¥é
åè奮ãšãæ·±ãé¢é£ããŠãããã®ãšããããçºçŸ
æ§åŒãç°ãã®ã¿ã§ãåå ã¯åäžã§ããå¯èœæ§ãé«
ãã ãããèºç ãŸãã¯èºç¶æ ã®è¬ç©çæ³ãšããŠã¯ã
ãããŸã§çš®ã ã®åŒ·å粟ç¥å®å®å€ãé©çšãããŠã
ãããŸãæè¿ã§ã¯çé žãªããŠã çã®ãªããŠã å€ã
èºç ã®æ²»çå€ãšããŠéçºããããšãããšãªã€ãã
ãŸãã«ã«ãããŒãã³ãæèºäœçšãæããããšãèŠ
ãã ãããã äžæ¹ã粟ç¥åè£çã®ç·åŒµåã«å¯ŸããŠã¯ã匷å粟
ç¥å®å®å€ãé©çšãããããšãå€ãã ãããããããã®è¬å€ãããã¯ãããã®è¬å€ã
çšããè¬ç©çæ³ãåã åé¡ç¹ãæããå¿ ãããæº
足ã®ãããã®ã§ã¯ãªããå³ã¡ã匷å粟ç¥å®å®å€ãš
ããŠã¯é®éäœçšã®åŒ·ãã¯ããŒã«ããããžã³ãã¬ã
ã¡ããããžã³çïŒä»¥äžãããšããã¢ãžã³ç³»è¬å€ïŒ
ãããããªããŒã«ïŒãããããšãã³ç³»è¬å€ïŒçã
奜ãã§çšãããããããããã®è¬å€ã®æ²»çã§ã¯ã
äžèªç¶ãªããé床ã®é®éå¹æãçŸãããããŸãã
ããã®è¬å€ã«ããåçš®ã®å¯äœçšïŒäŸãã°ãéäœå€
è·¯çç¶ïŒãèªããããå Žåãããã äžæ¹ãèºç ã®æ²»çãäž»å¹èœãšãããªããŠã å€ã§
ã¯æ¥µãèªç¶ãªåœ¢ã§ã®é®éå¹æããããããããšèš
ãå©ç¹ãããã ããããªããŠã å€ã®æè¬ã«ããã€ãŠã¯ãæ£è ã®
äžè¬è¡æ¶²æ€æ»ãå°¿æ€æ»ãå¿èæ€æ»ãè¡ãããšãã«
è çŸæ£ãšå¿èçŸæ£ãæããæ£è ãé€å€ããªããã°
ãªããªãããŸãå¬å¥åäœçšãããã®ã§åŠåš åæã
ãã³æä¹³äžã®æ£è ã察象ããé€å€ããå¿ èŠãã
ãã ãŸããçé žãªããŠã ã®æè¬ã«éããŠã泚æããª
ããã°ãªããªããã®ã«ããªããŠã äžæ¯ãããããª
ããŠã äžæ¯ã¯è¡äžãªããŠã æ¿åºŠã2.0mEqïŒïŒä»¥
äžã«ç¶ããŠããããããšçºçãããšãããããã
ãã以äžã®æ¿åºŠã§ãã€ãŠããªããŠã äžæ¯ã«é¥ãã
ãšãããã ãããã€ãŠãåžžã«ãªããŠã è¡äžæ¿åºŠæž¬å®ãèšåº
çç¶ã®èŠ³å¯ãå¿ èŠãšãããŠããã çé žãªããŠã ã«ããæ²»çã§ã¯å¹æçºçŸãŸã§ã«ïŒ
ãïŒæ¥éãèŠãããŸãäœçšã匷å粟ç¥å®å®å€ã«æ¯
ãç·©åã§ããã®ã§æ²»çã®åæãéçã®å Žåã«ã¯ã
åç¬æäžã§ã¯å¹æãæåŸ ã§ããªãå Žåãããã匷
å粟ç¥å®å®å€ãšã®äœµçšãå¿ ãšãªãããšããããæŽ
ã«èºç ã®æ²»çã«ãããŠã¯ãä»ã®ç²Ÿç¥çŸæ£ã®å Žåã
ãé¢åãªããšãå€ããå³ã¡ãèºç æ£è ã«ã¯äžè¬ã«
ç èãã¿ããããèªæææ ãé«ãŸã€ãŠããŠãä»äºº
ã®ããããšã容æã«èãããæ²»çã®å Žãžã®å°å ¥ã
å°é£ãªããšãæ²»çäžã®åæ±ãæ¥ãæ¹ã®é£ãããã
ãã 以äžã®ãããªäºæ ãããèºç ã«å¯ŸããŠç¹ç°çãª
å¹æãããããæ²»çè¬ãæ²»çæ¹æ³ã®ç¢ºç«ãæãŸã
ãŠããã ãŸã粟ç¥åè£çã®ç·åŒµåã«å¯ŸããŠãèºç ãšåæ§
ãªäºæ ãããã奜ãŸããæ²»çè¬ã®åºçŸãæãŸããŠ
ããã æ¬çºæè çã¯åèšã®ãããªèæ¯ã®ããšã«ãèºç
ã«ã¿ããããããªç²Ÿç¥éåè奮ã粟ç¥ã®ç°åžžãªè
奮ããããã¯ç²Ÿç¥åè£çã®ç·åŒµåã«ã¿ããã粟ç¥
éåè奮ã«å¯ŸããŠæå¶å¹æãããããæ°ããã¿ã€
ãã®è¬ç©ãéææ€èšããŠãããšããããšãªã¹ãâ
DOPSã«ãã®ç®çã«ããäœçšã®ããããšãèŠãåº
ããæ¬çºæã«è³ã€ããã®ã§ããã ïŒâïŒïŒïŒïŒâãžããããã·ããšãã«ïŒâã»ãªã³
ã¯DOPSãšç¥ç§°ãããè³éŠæã¢ããé žã§ãããã
ç«äœé 眮ã®å·®éã«ãããã¹ã¬ãªäœïŒã¹ã¬ãªâ
DOPSïŒãšãšãªã¹ãäœïŒãšãªã¹ãâDOPSïŒã®äº
çš®ãããããŸãåã ã«å åŠç°æ§äœãååšããã å³ã¡ãDOPSã«ã¯ãâã¹ã¬ãªâDOPSãšïŒ€â
ã¹ã¬ãªâDOPSããã³ïŒ¬âãšãªã¹ãªâDOPSãšïŒ€
âãšãªã¹ãâDOPSã®ïŒçš®ã®ç«äœç°æ§äœãããã
æŽã«ã¹ã¬ãªâDOPSãšãšãªã¹ãâDOPSã«ã¯
åã ãäœãšïŒ¬äœã®çéæ··åç©ã§ããã©ã»ãäœ
ïŒDLäœïŒãååšããã âDOPSã¯çäœå ã§è³éŠæâã¢ããé žè±ç
é žé µçŽ ã®åãã«ãããè±çé žåå¿ãåãããã«ã¢
ãã¬ããªã³ïŒä»¥äžãNAãšããïŒã«å€æãããã
ãšãæ¢ã«ç¥ãããŠããããŸãçæãããNAã
âã¹ã¬ãªâDOPSããã¯å€©ç¶åã®ïœâNAïŒè³å
ã«ããšããšååšããïŒããâãšãªã¹ãâDOPS
ããã¯é倩ç¶åã®ïœâNAãçæããããšãå ±å
ãããŠããã äžæ¹ãDOPSã®æã€è¬çäœçšã«ã€ããŠãããã
ã€ãã®å ±åããããå³ã¡ãåç©ãçšããè¬çåŠç
è©ŠéšãããDOPSãæãã€äœçšãææ¯ããäœçšã
æé«è¡å§äœçšã瀺ãããšãå ±åãããŠããããŸã
èšåºè©Šéšã®çµæã«åºã¥ãDLä¹è³ïŒ¬âã¹ã¬ãªâ
DOPSã®èµ·ç«æ§äœè¡å§çãããŒãã³ãœã³æ°ç ã«ã
ããããã¿çç¶ã«å¯Ÿããæå¹æ§ãå ±åãããŠã
ãã ãšããã§ãæ¬çºæè çã¯ãšãªã¹ãâDOPSãå
ç©ã«æäžãããã®è¬çäœçšãæ€èšããçµæãå®éš
äŸïŒãïŒã«ç€ºãåŠãæ¬å€ã粟ç¥éåè奮ãæå¶ã
ãããšãèŠãåºããŠæ¬çºæãå®æããã 粟ç¥éåè奮ã¯èºç ãç·åŒµç ãç¹åŸŽã¥ããäž»ç
ç¶ã§ããããšãèãããšãããã«ãšãªã¹ãâ
DOPSã®èºç ãªããç·åŒµç ã®æ¹åãæ²»çã®çšéã
èŠåºãããããšã«ãªããæ¬çºæã®ç²Ÿç¥éåè奮æ
å¶äœçšã¯æ¬¡ã®äœçšã«åºã¥ããšè§£éãããã æ¬çºæè çã¯ããšãªã¹ãâDOPSãåç©ã«æäž
ããæã®è³å ã¢ãã³ïŒNAãããŒããã³ãã»ãã
ãã³ïŒã®å«éã®å€åã«ã€ããŠãçååŠçã«æ€èšã
ãããã®çµæãå®éšäŸïŒãïŒã«ç€ºãåŠãNAã®ã¿
ãé¡èã«äžæããŠããããšãèŠãåºãããããã®
NAã®äžæã¯ãçäœå ã®è³éŠæâã¢ããé žè±é ž
é µçŽ ã®åããåããŠçããâãšãªã¹ãâDOPS
ããã®ïœâNAïŒé倩ç¶åïŒã«ãããã®ãšèãã
ããã äžæ¹ãèºç ãªããèºç¶æ ãšè³å ã¢ãã³ãšã®é¢ä¿
ã«ã€ããŠã¯ãããŸã§ãããªãã®ç 究ããªãããŠã
ãããèºç¶æ ã§ã¯NAïŒå€©ç¶åïŒã®ä»£è¬å転ã®äº¢
é²ããããšããå ±åããããNAäœåæ§ç¥çµã®é«
ãŸããšçžé¢ãããšããèããäžè¬çã§ããã åŸã€ãŠãæ¬çºæè ãããšãã«åŸããŸãã¯DL
ã®ãšãªã¹ãâDOPSæäžã«ãã粟ç¥éåè奮æå¶
äœçšã¯æäžãããâãšãªã¹ãâDOPSããçã
ãè³å ã§ã®ïœâNAã®äžæããNAäœåæ§ç¥çµç³»
ã®è奮ãæå¶ããæ¹åã§äœçšããŠãããã®ãšè§£é
ããããšãã§ããã æ¬çºæã§èšããšãªã¹ãâDOPSã¯ãè³éŠæâ
ã¢ããé žè±çé žé µçŽ ã®åºè³ªã«ãªãåŸããã®ã§ãã
ããšãããâãšãªã¹ãâDOPSãŸãã¯DLãšãª
ã¹ãâDOPSãæå³ããããçã¯æ¢ã«å ¬ç¥ã®æ¹æ³
ã§åŸãããšãåºæ¥ãã 以äžã«æ¬çºæã«ã€ããŠæŽã«è©³ãã説æããã ãšãªã¹ãâDOPSã®ç²Ÿç¥éåè奮æå¶äœçšã¯å®éš
äŸïŒïŒïŒããã³ïŒã«ç€ºãããŠã¹ãçšããå®éšã«ã
ãèŠåºãããã®ã§ãããäžæ¹ããšãªã¹ãâDOPS
ã®æäžã«ããè³å NAéã®å¢å ã¯å®éšäŸïŒããã³
ïŒã«ããèŠåºãããã®ã§ããã ïŒå®éšäŸ ïŒïŒ ããŠã¹ïŒå¹ãäžçŸ€ãšããŠã¢ãã¡ãã¯ã¹
ïŒAnimexïŒã®éå枬å®ç®±ã«å ¥ããŠãçµæçã«ã
ãŠã¹ã®èªçºéåéã枬å®ããã ããŠã¹ã¯éå枬å®ç®±ã«å ¥ããããšã«ãããæ¢çŽ¢
è¡åçãè¡ããé«ãèªçºéåéã瀺ããã次第ã«
èœçããçŽ30â40åã§è¹²ãããã«ãªããèªçºéå
éã¯æ¥µå°ãšãªããã¢ãã¢ãã³ãªãã·ããŒãŒãé»å®³
å€ïŒMAOIïŒã§ããβâããšãã«ã€ãœãããã«ã
ãã©ãžã³å¡©é žå¡©ïŒã«ããã³ïŒïŒä»¥äžãPIHãšããïŒ
50mgïŒKgãè ¹è å ã«æäžãã16æéçµéããããŠ
ã¹ãçšããŠäžèšã®å®éšãè¡ãªããšãèªçºéåéã®
å¢å ãšãèœã¡çããŸã§ã®æéãé·ããªãåŸåãèª
ããããã ãã®ãããªå®éšç³»ã«å¯ŸããDLâãšãªã¹ãâ
DOPSã200mgïŒKgãè ¹è å 泚å°ããæã®åœ±é¿ã«
ã€ããŠæ€èšããã ãã®çµæã第ïŒå³ã«ç€ºãããã«ãèªçºéåéã®
èæãªæžå°ãèªããããã ïŒå®éšäŸ ïŒïŒ å®éšäŸïŒãšåããããŠã¹ã®èªçºéåé枬å®å®éš
ç³»ãçšãããèŠéã¢ãã³ã§ããã¡ã¿ã³ããšã¿ãã³
ïŒ1.4mgïŒKgïŒãè ¹è å ã«æäžãããšãèªçºéåé
ã¯æ¥æ¿ã«å¢å ãã泚å°åŸ50åã§æžå°åŸåãå§ãŸ
ããïŒæéåŸã«ã¯ã»ãŒå ã®ç¶æ ã«ãããã ããã«å¯ŸããDLâãšãªã¹ãâDOPSïŒ200mgïŒ
KgïŒãåæã«è ¹è å ã«æäžãããšãéåéã®å¢å
ã¯èæã§ãªããã¡ã¿ã³ããšã¿ãã³ã«ããèªçºéå
å¢å äœçšãæå¶ãããïŒç¬¬ïŒå³ïŒ ïŒå®éšäŸ ïŒïŒ å®éšäŸïŒãšåããããŠã¹ã®èªçºéåé枬å®å®éš
ç³»ãçšããã MAOIã§ãããã©ããŒã«ã·ããã³ã50mgïŒKgã
è ¹è å ã«æäžãããšãããŠã¹ã®èªçºéåã¯æŒžæ¬¡å¢
å ããæäžåŸ120åã§æé«ã«å¯Ÿãããã®éåéã
ç¶æããããã«ãªãã ããã«å¯Ÿãã180ååŸã«DLâãšãªã¹ãâDOPS
ãæäžãããšçŽ20åã§éåéã®æžå°ãå§ãŸãã30
ã90åéç¶ããã€ãã§æŒžæ¬¡å¢å ãå§ãå ã®å¢å ã
ãç¶æ ã«ããã€ãïŒç¬¬ïŒå³ïŒã ïŒå®éšäŸ ïŒïŒ ããŠã¹ã«çççé£å¡©æ°ŽãªããPIHã50mgïŒKgã
è ¹è å 泚å°ã17æéåŸã«è³å ã¢ãã³å«éã枬å®ã
ãã 枬å®æ³ã¯Ogasawaraçã®æ¹æ³ïŒJ.Chromatogr.
180ïŒ119ïŒã«ã»ãŒæºãããå€ã¯ïœïœïŒïœæ¹¿ééã§
è¡šãããïŒå¹ã®å¹³åå€Â±SDã§ç€ºãããâ»ïŒïŒ°ïŒ
0.005â»â»ïŒïŒ°ïŒ0.05 ãè¡šã ïŒå®éšäŸ ïŒïŒ ããŠã¹ã«PIHã50mgïŒKgãååŠçœ®ãã17æéåŸ
ã«çççé£å¡©æ°ŽãªããDLâãšãªã¹ãâDOPSã
200mgïŒKgãè ¹è å 泚å°ãããã€ãã§æ³šå°åŸ30å
åŸã®è³å ã¢ãã³å«éã枬å®ãããå€ã¯ïœïœïŒïœæ¹¿
ééã§è¡šãããïŒå¹ã®å¹³åå€Â±SDã§ç€ºããã â»ïŒïŒ°ïŒ0.005 ãè¡šã ãŸããåœè©²ãšãªã¹ãâDOPSã¯è¬åŠçã«èš±å®¹ã
ããé žéå å¡©ã®åã§ãçšããããšãã§ãããå³ã¡
å¡©é žãèåæ°ŽçŽ é žãç¡«é žçã®ç¡æ©é žããããŒã«
é žãã¯ãšã³é žãé ç³é žãã³ãã¯é žçã®ææ©é žãé
å 塩圢æçšé žãšããŠãããããã æ¬çºæã®æŽ»æ§ååç©ã§ãããšãªã¹ãâDOPS
ã¯ãåã ã®å¿ èŠæ§ã«é©å¿ããæäžéã§çµå£çãŸã
ã¯éçµå£çã«æäžããããšãã§ãããå³ã¡ãã®æ²»
çæäžéãæ®éã®æäžåœ¢æ ãäŸãã°é å€ãã«ãã»
ã«é ãã·ãããå€ãæžæ¿æ¶²çã®åã§çµå£çã«æäž
ããããšãã§ãããããã¯ããŸããã®æº¶æ¶²ãä¹³
å€ãæžæ¿æ¶²çã®æ¶²å€ã®åã«ãããã®ã泚å°ã®åã§
éæœå£æäžããããšãã§ããã ãŸããåèšã®é©åœãªæäžå€åã¯èš±å®¹ãããéåžž
ã®æ äœã賊åå€ãçµåå€ãå®å®å€ãªã©ã«æŽ»æ§åå
ç©ãé åããããšã«ãã補é ããããšãã§ããã
ãŸã泚å°å€åã§çšããå Žåã«ã¯èš±å®¹ãããç·©è¡
å€ã溶解è£å©å€ãç匵å€çãæ·»å ããããšãã§ã
ãã æ¬é¡ã«çšãããšãªã¹ãâDOPSã®æäžéãæäž
åæ°ã¯ãæäžåœ¢æ ãããã¯æ²»çãèŠãã粟ç¥éå
è奮ã®çç¶ã®çšåºŠã«ãã€ãŠç°ãªãããäŸãã°çµå£
æäžã®å Žåã¯æ人ïŒæ¥åœã0.1ãïŒïœãïŒåãŸã
ã¯æ°åã«åããŠããããšãã§ããã ãŸãéè泚å°ã®å Žåã¯ãæ人ïŒæ¥åœã0.1ãïŒ
ïœãïŒåãŸãã¯æ°åã«åããŠæäžããããšãã§ã
ãã ãªãããšãªã¹ãâDOPSã®è³å ãžã®ç§»è¡ããã
ããããçºã«ãšã³ããã€ã¶ãŒïŒeconomizerïŒã®
圹ç®ãããæ«æ¢¢æ§è±çé žé µçŽ é»å®³å€ïŒä»¥äžãDCI
ãšããïŒã䜵çšããããšãã§ããã DCIãšããŠã¯äŸãã°ã«ã«ãããïŒcarbidopaïŒ
ããã³ã»ã©ãžãïŒbenserazideïŒãæããããšã
åºæ¥ãã äžæ¹ãDCIã®æäžéã¯ããšãªã¹ãâDOPSã«å¯Ÿ
ããŠãããå¹ ããã€ãŠçšããããšãåºæ¥ãããäž
è¬çã«ã¯ãšãªã¹ãâDOPSã«å¯ŸããŠ0.025ã0.5ã¢
ã«æ¯ã®ç¯å²ã§çšããããšãåºæ¥ãã 次ã«ãããã«çšãããšãªã¹ãâDOPSã®æ¯æ§ã¯
極ããŠåŒ±ããããŠã¹ã«ãããLD50å€ã¯çµå£æäž
ã§ïŒïœïŒKg以äžã§ããã
âãžããããã·ããšãã«ïŒâã»ãªã³ïŒä»¥äžããšãª
ã¹ãâDOPSãšããïŒãŸãã¯ãã®å¡©ãæå¹æåãš
ãã粟ç¥éåè奮æå¶å€ã«é¢ããã 粟ç¥éåã®é床ãªè奮ã¯ãããã€ãã®ç²Ÿç¥ç¥çµ
çŸæ£ã®ç¹åŸŽççç¶ãšããŠçŸãããã®ã§ãããäŸã
ã°èºïŒãã€ïŒç ã®èºç çžã«ãããå Žåãã粟ç¥å
è£ç ãšãã«ãã®ç·åŒµåã«ãããå Žåãªã©ãã®ä»£è¡š
çäŸç€ºãšèšããã åŸã€ãŠãæ¬çºæã¯ç²Ÿç¥éåè奮ãäž»çåãšãã
èºç ã粟ç¥åè£ç ã®ç·åŒµåã«å¯Ÿããçç¶ã®æ¹åã
æ²»çå€ãšããŠã®ãšãªã¹ãâDOPSã®çšéã«ä¿ãã
ã®ã§ããã èºç ã§ã¯çœå¿«æ°åãåºææ§æ°åãæç¶ãããã
é«æããæ°åãããã¯èŠ³å¿µå¥éžãèªæææ ã®äº¢é²
ãèªãããããããããã®ç²Ÿç¥é«æã¯å ã®ç²Ÿç¥é
åè奮ãšãæ·±ãé¢é£ããŠãããã®ãšããããçºçŸ
æ§åŒãç°ãã®ã¿ã§ãåå ã¯åäžã§ããå¯èœæ§ãé«
ãã ãããèºç ãŸãã¯èºç¶æ ã®è¬ç©çæ³ãšããŠã¯ã
ãããŸã§çš®ã ã®åŒ·å粟ç¥å®å®å€ãé©çšãããŠã
ãããŸãæè¿ã§ã¯çé žãªããŠã çã®ãªããŠã å€ã
èºç ã®æ²»çå€ãšããŠéçºããããšãããšãªã€ãã
ãŸãã«ã«ãããŒãã³ãæèºäœçšãæããããšãèŠ
ãã ãããã äžæ¹ã粟ç¥åè£çã®ç·åŒµåã«å¯ŸããŠã¯ã匷å粟
ç¥å®å®å€ãé©çšãããããšãå€ãã ãããããããã®è¬å€ãããã¯ãããã®è¬å€ã
çšããè¬ç©çæ³ãåã åé¡ç¹ãæããå¿ ãããæº
足ã®ãããã®ã§ã¯ãªããå³ã¡ã匷å粟ç¥å®å®å€ãš
ããŠã¯é®éäœçšã®åŒ·ãã¯ããŒã«ããããžã³ãã¬ã
ã¡ããããžã³çïŒä»¥äžãããšããã¢ãžã³ç³»è¬å€ïŒ
ãããããªããŒã«ïŒãããããšãã³ç³»è¬å€ïŒçã
奜ãã§çšãããããããããã®è¬å€ã®æ²»çã§ã¯ã
äžèªç¶ãªããé床ã®é®éå¹æãçŸãããããŸãã
ããã®è¬å€ã«ããåçš®ã®å¯äœçšïŒäŸãã°ãéäœå€
è·¯çç¶ïŒãèªããããå Žåãããã äžæ¹ãèºç ã®æ²»çãäž»å¹èœãšãããªããŠã å€ã§
ã¯æ¥µãèªç¶ãªåœ¢ã§ã®é®éå¹æããããããããšèš
ãå©ç¹ãããã ããããªããŠã å€ã®æè¬ã«ããã€ãŠã¯ãæ£è ã®
äžè¬è¡æ¶²æ€æ»ãå°¿æ€æ»ãå¿èæ€æ»ãè¡ãããšãã«
è çŸæ£ãšå¿èçŸæ£ãæããæ£è ãé€å€ããªããã°
ãªããªãããŸãå¬å¥åäœçšãããã®ã§åŠåš åæã
ãã³æä¹³äžã®æ£è ã察象ããé€å€ããå¿ èŠãã
ãã ãŸããçé žãªããŠã ã®æè¬ã«éããŠã泚æããª
ããã°ãªããªããã®ã«ããªããŠã äžæ¯ãããããª
ããŠã äžæ¯ã¯è¡äžãªããŠã æ¿åºŠã2.0mEqïŒïŒä»¥
äžã«ç¶ããŠããããããšçºçãããšãããããã
ãã以äžã®æ¿åºŠã§ãã€ãŠããªããŠã äžæ¯ã«é¥ãã
ãšãããã ãããã€ãŠãåžžã«ãªããŠã è¡äžæ¿åºŠæž¬å®ãèšåº
çç¶ã®èŠ³å¯ãå¿ èŠãšãããŠããã çé žãªããŠã ã«ããæ²»çã§ã¯å¹æçºçŸãŸã§ã«ïŒ
ãïŒæ¥éãèŠãããŸãäœçšã匷å粟ç¥å®å®å€ã«æ¯
ãç·©åã§ããã®ã§æ²»çã®åæãéçã®å Žåã«ã¯ã
åç¬æäžã§ã¯å¹æãæåŸ ã§ããªãå Žåãããã匷
å粟ç¥å®å®å€ãšã®äœµçšãå¿ ãšãªãããšããããæŽ
ã«èºç ã®æ²»çã«ãããŠã¯ãä»ã®ç²Ÿç¥çŸæ£ã®å Žåã
ãé¢åãªããšãå€ããå³ã¡ãèºç æ£è ã«ã¯äžè¬ã«
ç èãã¿ããããèªæææ ãé«ãŸã€ãŠããŠãä»äºº
ã®ããããšã容æã«èãããæ²»çã®å Žãžã®å°å ¥ã
å°é£ãªããšãæ²»çäžã®åæ±ãæ¥ãæ¹ã®é£ãããã
ãã 以äžã®ãããªäºæ ãããèºç ã«å¯ŸããŠç¹ç°çãª
å¹æãããããæ²»çè¬ãæ²»çæ¹æ³ã®ç¢ºç«ãæãŸã
ãŠããã ãŸã粟ç¥åè£çã®ç·åŒµåã«å¯ŸããŠãèºç ãšåæ§
ãªäºæ ãããã奜ãŸããæ²»çè¬ã®åºçŸãæãŸããŠ
ããã æ¬çºæè çã¯åèšã®ãããªèæ¯ã®ããšã«ãèºç
ã«ã¿ããããããªç²Ÿç¥éåè奮ã粟ç¥ã®ç°åžžãªè
奮ããããã¯ç²Ÿç¥åè£çã®ç·åŒµåã«ã¿ããã粟ç¥
éåè奮ã«å¯ŸããŠæå¶å¹æãããããæ°ããã¿ã€
ãã®è¬ç©ãéææ€èšããŠãããšããããšãªã¹ãâ
DOPSã«ãã®ç®çã«ããäœçšã®ããããšãèŠãåº
ããæ¬çºæã«è³ã€ããã®ã§ããã ïŒâïŒïŒïŒïŒâãžããããã·ããšãã«ïŒâã»ãªã³
ã¯DOPSãšç¥ç§°ãããè³éŠæã¢ããé žã§ãããã
ç«äœé 眮ã®å·®éã«ãããã¹ã¬ãªäœïŒã¹ã¬ãªâ
DOPSïŒãšãšãªã¹ãäœïŒãšãªã¹ãâDOPSïŒã®äº
çš®ãããããŸãåã ã«å åŠç°æ§äœãååšããã å³ã¡ãDOPSã«ã¯ãâã¹ã¬ãªâDOPSãšïŒ€â
ã¹ã¬ãªâDOPSããã³ïŒ¬âãšãªã¹ãªâDOPSãšïŒ€
âãšãªã¹ãâDOPSã®ïŒçš®ã®ç«äœç°æ§äœãããã
æŽã«ã¹ã¬ãªâDOPSãšãšãªã¹ãâDOPSã«ã¯
åã ãäœãšïŒ¬äœã®çéæ··åç©ã§ããã©ã»ãäœ
ïŒDLäœïŒãååšããã âDOPSã¯çäœå ã§è³éŠæâã¢ããé žè±ç
é žé µçŽ ã®åãã«ãããè±çé žåå¿ãåãããã«ã¢
ãã¬ããªã³ïŒä»¥äžãNAãšããïŒã«å€æãããã
ãšãæ¢ã«ç¥ãããŠããããŸãçæãããNAã
âã¹ã¬ãªâDOPSããã¯å€©ç¶åã®ïœâNAïŒè³å
ã«ããšããšååšããïŒããâãšãªã¹ãâDOPS
ããã¯é倩ç¶åã®ïœâNAãçæããããšãå ±å
ãããŠããã äžæ¹ãDOPSã®æã€è¬çäœçšã«ã€ããŠãããã
ã€ãã®å ±åããããå³ã¡ãåç©ãçšããè¬çåŠç
è©ŠéšãããDOPSãæãã€äœçšãææ¯ããäœçšã
æé«è¡å§äœçšã瀺ãããšãå ±åãããŠããããŸã
èšåºè©Šéšã®çµæã«åºã¥ãDLä¹è³ïŒ¬âã¹ã¬ãªâ
DOPSã®èµ·ç«æ§äœè¡å§çãããŒãã³ãœã³æ°ç ã«ã
ããããã¿çç¶ã«å¯Ÿããæå¹æ§ãå ±åãããŠã
ãã ãšããã§ãæ¬çºæè çã¯ãšãªã¹ãâDOPSãå
ç©ã«æäžãããã®è¬çäœçšãæ€èšããçµæãå®éš
äŸïŒãïŒã«ç€ºãåŠãæ¬å€ã粟ç¥éåè奮ãæå¶ã
ãããšãèŠãåºããŠæ¬çºæãå®æããã 粟ç¥éåè奮ã¯èºç ãç·åŒµç ãç¹åŸŽã¥ããäž»ç
ç¶ã§ããããšãèãããšãããã«ãšãªã¹ãâ
DOPSã®èºç ãªããç·åŒµç ã®æ¹åãæ²»çã®çšéã
èŠåºãããããšã«ãªããæ¬çºæã®ç²Ÿç¥éåè奮æ
å¶äœçšã¯æ¬¡ã®äœçšã«åºã¥ããšè§£éãããã æ¬çºæè çã¯ããšãªã¹ãâDOPSãåç©ã«æäž
ããæã®è³å ã¢ãã³ïŒNAãããŒããã³ãã»ãã
ãã³ïŒã®å«éã®å€åã«ã€ããŠãçååŠçã«æ€èšã
ãããã®çµæãå®éšäŸïŒãïŒã«ç€ºãåŠãNAã®ã¿
ãé¡èã«äžæããŠããããšãèŠãåºãããããã®
NAã®äžæã¯ãçäœå ã®è³éŠæâã¢ããé žè±é ž
é µçŽ ã®åããåããŠçããâãšãªã¹ãâDOPS
ããã®ïœâNAïŒé倩ç¶åïŒã«ãããã®ãšèãã
ããã äžæ¹ãèºç ãªããèºç¶æ ãšè³å ã¢ãã³ãšã®é¢ä¿
ã«ã€ããŠã¯ãããŸã§ãããªãã®ç 究ããªãããŠã
ãããèºç¶æ ã§ã¯NAïŒå€©ç¶åïŒã®ä»£è¬å転ã®äº¢
é²ããããšããå ±åããããNAäœåæ§ç¥çµã®é«
ãŸããšçžé¢ãããšããèããäžè¬çã§ããã åŸã€ãŠãæ¬çºæè ãããšãã«åŸããŸãã¯DL
ã®ãšãªã¹ãâDOPSæäžã«ãã粟ç¥éåè奮æå¶
äœçšã¯æäžãããâãšãªã¹ãâDOPSããçã
ãè³å ã§ã®ïœâNAã®äžæããNAäœåæ§ç¥çµç³»
ã®è奮ãæå¶ããæ¹åã§äœçšããŠãããã®ãšè§£é
ããããšãã§ããã æ¬çºæã§èšããšãªã¹ãâDOPSã¯ãè³éŠæâ
ã¢ããé žè±çé žé µçŽ ã®åºè³ªã«ãªãåŸããã®ã§ãã
ããšãããâãšãªã¹ãâDOPSãŸãã¯DLãšãª
ã¹ãâDOPSãæå³ããããçã¯æ¢ã«å ¬ç¥ã®æ¹æ³
ã§åŸãããšãåºæ¥ãã 以äžã«æ¬çºæã«ã€ããŠæŽã«è©³ãã説æããã ãšãªã¹ãâDOPSã®ç²Ÿç¥éåè奮æå¶äœçšã¯å®éš
äŸïŒïŒïŒããã³ïŒã«ç€ºãããŠã¹ãçšããå®éšã«ã
ãèŠåºãããã®ã§ãããäžæ¹ããšãªã¹ãâDOPS
ã®æäžã«ããè³å NAéã®å¢å ã¯å®éšäŸïŒããã³
ïŒã«ããèŠåºãããã®ã§ããã ïŒå®éšäŸ ïŒïŒ ããŠã¹ïŒå¹ãäžçŸ€ãšããŠã¢ãã¡ãã¯ã¹
ïŒAnimexïŒã®éå枬å®ç®±ã«å ¥ããŠãçµæçã«ã
ãŠã¹ã®èªçºéåéã枬å®ããã ããŠã¹ã¯éå枬å®ç®±ã«å ¥ããããšã«ãããæ¢çŽ¢
è¡åçãè¡ããé«ãèªçºéåéã瀺ããã次第ã«
èœçããçŽ30â40åã§è¹²ãããã«ãªããèªçºéå
éã¯æ¥µå°ãšãªããã¢ãã¢ãã³ãªãã·ããŒãŒãé»å®³
å€ïŒMAOIïŒã§ããβâããšãã«ã€ãœãããã«ã
ãã©ãžã³å¡©é žå¡©ïŒã«ããã³ïŒïŒä»¥äžãPIHãšããïŒ
50mgïŒKgãè ¹è å ã«æäžãã16æéçµéããããŠ
ã¹ãçšããŠäžèšã®å®éšãè¡ãªããšãèªçºéåéã®
å¢å ãšãèœã¡çããŸã§ã®æéãé·ããªãåŸåãèª
ããããã ãã®ãããªå®éšç³»ã«å¯ŸããDLâãšãªã¹ãâ
DOPSã200mgïŒKgãè ¹è å 泚å°ããæã®åœ±é¿ã«
ã€ããŠæ€èšããã ãã®çµæã第ïŒå³ã«ç€ºãããã«ãèªçºéåéã®
èæãªæžå°ãèªããããã ïŒå®éšäŸ ïŒïŒ å®éšäŸïŒãšåããããŠã¹ã®èªçºéåé枬å®å®éš
ç³»ãçšãããèŠéã¢ãã³ã§ããã¡ã¿ã³ããšã¿ãã³
ïŒ1.4mgïŒKgïŒãè ¹è å ã«æäžãããšãèªçºéåé
ã¯æ¥æ¿ã«å¢å ãã泚å°åŸ50åã§æžå°åŸåãå§ãŸ
ããïŒæéåŸã«ã¯ã»ãŒå ã®ç¶æ ã«ãããã ããã«å¯ŸããDLâãšãªã¹ãâDOPSïŒ200mgïŒ
KgïŒãåæã«è ¹è å ã«æäžãããšãéåéã®å¢å
ã¯èæã§ãªããã¡ã¿ã³ããšã¿ãã³ã«ããèªçºéå
å¢å äœçšãæå¶ãããïŒç¬¬ïŒå³ïŒ ïŒå®éšäŸ ïŒïŒ å®éšäŸïŒãšåããããŠã¹ã®èªçºéåé枬å®å®éš
ç³»ãçšããã MAOIã§ãããã©ããŒã«ã·ããã³ã50mgïŒKgã
è ¹è å ã«æäžãããšãããŠã¹ã®èªçºéåã¯æŒžæ¬¡å¢
å ããæäžåŸ120åã§æé«ã«å¯Ÿãããã®éåéã
ç¶æããããã«ãªãã ããã«å¯Ÿãã180ååŸã«DLâãšãªã¹ãâDOPS
ãæäžãããšçŽ20åã§éåéã®æžå°ãå§ãŸãã30
ã90åéç¶ããã€ãã§æŒžæ¬¡å¢å ãå§ãå ã®å¢å ã
ãç¶æ ã«ããã€ãïŒç¬¬ïŒå³ïŒã ïŒå®éšäŸ ïŒïŒ ããŠã¹ã«çççé£å¡©æ°ŽãªããPIHã50mgïŒKgã
è ¹è å 泚å°ã17æéåŸã«è³å ã¢ãã³å«éã枬å®ã
ãã 枬å®æ³ã¯Ogasawaraçã®æ¹æ³ïŒJ.Chromatogr.
180ïŒ119ïŒã«ã»ãŒæºãããå€ã¯ïœïœïŒïœæ¹¿ééã§
è¡šãããïŒå¹ã®å¹³åå€Â±SDã§ç€ºãããâ»ïŒïŒ°ïŒ
0.005â»â»ïŒïŒ°ïŒ0.05 ãè¡šã ïŒå®éšäŸ ïŒïŒ ããŠã¹ã«PIHã50mgïŒKgãååŠçœ®ãã17æéåŸ
ã«çççé£å¡©æ°ŽãªããDLâãšãªã¹ãâDOPSã
200mgïŒKgãè ¹è å 泚å°ãããã€ãã§æ³šå°åŸ30å
åŸã®è³å ã¢ãã³å«éã枬å®ãããå€ã¯ïœïœïŒïœæ¹¿
ééã§è¡šãããïŒå¹ã®å¹³åå€Â±SDã§ç€ºããã â»ïŒïŒ°ïŒ0.005 ãè¡šã ãŸããåœè©²ãšãªã¹ãâDOPSã¯è¬åŠçã«èš±å®¹ã
ããé žéå å¡©ã®åã§ãçšããããšãã§ãããå³ã¡
å¡©é žãèåæ°ŽçŽ é žãç¡«é žçã®ç¡æ©é žããããŒã«
é žãã¯ãšã³é žãé ç³é žãã³ãã¯é žçã®ææ©é žãé
å 塩圢æçšé žãšããŠãããããã æ¬çºæã®æŽ»æ§ååç©ã§ãããšãªã¹ãâDOPS
ã¯ãåã ã®å¿ èŠæ§ã«é©å¿ããæäžéã§çµå£çãŸã
ã¯éçµå£çã«æäžããããšãã§ãããå³ã¡ãã®æ²»
çæäžéãæ®éã®æäžåœ¢æ ãäŸãã°é å€ãã«ãã»
ã«é ãã·ãããå€ãæžæ¿æ¶²çã®åã§çµå£çã«æäž
ããããšãã§ãããããã¯ããŸããã®æº¶æ¶²ãä¹³
å€ãæžæ¿æ¶²çã®æ¶²å€ã®åã«ãããã®ã泚å°ã®åã§
éæœå£æäžããããšãã§ããã ãŸããåèšã®é©åœãªæäžå€åã¯èš±å®¹ãããéåžž
ã®æ äœã賊åå€ãçµåå€ãå®å®å€ãªã©ã«æŽ»æ§åå
ç©ãé åããããšã«ãã補é ããããšãã§ããã
ãŸã泚å°å€åã§çšããå Žåã«ã¯èš±å®¹ãããç·©è¡
å€ã溶解è£å©å€ãç匵å€çãæ·»å ããããšãã§ã
ãã æ¬é¡ã«çšãããšãªã¹ãâDOPSã®æäžéãæäž
åæ°ã¯ãæäžåœ¢æ ãããã¯æ²»çãèŠãã粟ç¥éå
è奮ã®çç¶ã®çšåºŠã«ãã€ãŠç°ãªãããäŸãã°çµå£
æäžã®å Žåã¯æ人ïŒæ¥åœã0.1ãïŒïœãïŒåãŸã
ã¯æ°åã«åããŠããããšãã§ããã ãŸãéè泚å°ã®å Žåã¯ãæ人ïŒæ¥åœã0.1ãïŒ
ïœãïŒåãŸãã¯æ°åã«åããŠæäžããããšãã§ã
ãã ãªãããšãªã¹ãâDOPSã®è³å ãžã®ç§»è¡ããã
ããããçºã«ãšã³ããã€ã¶ãŒïŒeconomizerïŒã®
圹ç®ãããæ«æ¢¢æ§è±çé žé µçŽ é»å®³å€ïŒä»¥äžãDCI
ãšããïŒã䜵çšããããšãã§ããã DCIãšããŠã¯äŸãã°ã«ã«ãããïŒcarbidopaïŒ
ããã³ã»ã©ãžãïŒbenserazideïŒãæããããšã
åºæ¥ãã äžæ¹ãDCIã®æäžéã¯ããšãªã¹ãâDOPSã«å¯Ÿ
ããŠãããå¹ ããã€ãŠçšããããšãåºæ¥ãããäž
è¬çã«ã¯ãšãªã¹ãâDOPSã«å¯ŸããŠ0.025ã0.5ã¢
ã«æ¯ã®ç¯å²ã§çšããããšãåºæ¥ãã 次ã«ãããã«çšãããšãªã¹ãâDOPSã®æ¯æ§ã¯
極ããŠåŒ±ããããŠã¹ã«ãããLD50å€ã¯çµå£æäž
ã§ïŒïœïŒKg以äžã§ããã
第ïŒå³ã¯ããŠã¹ã®èªçºéåéã«ãããŒãDLâ
ãšãªã¹ãâDOPSã®åœ±é¿ãã¿ããã®ã§ããã瞊軞
ã¯éåécountsïŒ5minãã暪軞ã¯DLâãšãªã¹ã
âDOPSæäžåŸã30ååŸããèªçºéåéã枬å®ã
ã¯ãããŠããã®æéïŒåïŒãè¡šããã ããã¯PIH50mgïŒKgè ¹è å æäžã®ã¿ã®å Žåãâ¡
ã¯PIHãšå ±ã«DLâãšãªã¹ãâDOPSã200mgïŒKg
è ¹è å æäžããå Žåãè¡šããã第ïŒå³ã¯ã¡ã¿ã³ã
ãšã¿ãã³ã«ããããŠã¹ã®èªçºéåéå¢å ã«å¯Ÿãã
DLâãšãªã¹ãâDOPSã®åœ±é¿ãã¿ããã®ã§ããã
瞊軞ã¯èªçºéåéã暪軞ã¯ã¡ã¿ã³ããšã¿ãã³
ïŒïŒãïŒmgïŒKgïŒåç¬ãŸãã¯ã¡ã¿ã³ããšã¿ãã³ãš
DLâãšãªã¹ãâDOPSïŒ200mgïŒKgïŒãåææäž
ããæãïŒç¹ãšããæéçµéïŒåïŒãè¡šãããâ¡
ã¯ã¡ã¿ã³ããšã¿ãã³åç¬æäžã®å Žåãããã¯ã¡ã¿
ã³ããšã¿ãã³ãšDLâãšãªã¹ãâDOPSãåææ
äžããå Žåãè¡šããã第ïŒå³ã¯ãã©ããŒã«ããã
ã³æäžããŠã¹ã®èªçºéåéã«ãããŒãDLâãšãª
ã¹ãâDOPSã®åœ±é¿ãã¿ããã®ã§ããã瞊軞ã¯èª
çºéåéãè¡šããã暪軞ã¯æéçµéïŒåïŒãè¡šã
ããç¢å°ã¯æè¬æéãè¡šããã
ãšãªã¹ãâDOPSã®åœ±é¿ãã¿ããã®ã§ããã瞊軞
ã¯éåécountsïŒ5minãã暪軞ã¯DLâãšãªã¹ã
âDOPSæäžåŸã30ååŸããèªçºéåéã枬å®ã
ã¯ãããŠããã®æéïŒåïŒãè¡šããã ããã¯PIH50mgïŒKgè ¹è å æäžã®ã¿ã®å Žåãâ¡
ã¯PIHãšå ±ã«DLâãšãªã¹ãâDOPSã200mgïŒKg
è ¹è å æäžããå Žåãè¡šããã第ïŒå³ã¯ã¡ã¿ã³ã
ãšã¿ãã³ã«ããããŠã¹ã®èªçºéåéå¢å ã«å¯Ÿãã
DLâãšãªã¹ãâDOPSã®åœ±é¿ãã¿ããã®ã§ããã
瞊軞ã¯èªçºéåéã暪軞ã¯ã¡ã¿ã³ããšã¿ãã³
ïŒïŒãïŒmgïŒKgïŒåç¬ãŸãã¯ã¡ã¿ã³ããšã¿ãã³ãš
DLâãšãªã¹ãâDOPSïŒ200mgïŒKgïŒãåææäž
ããæãïŒç¹ãšããæéçµéïŒåïŒãè¡šãããâ¡
ã¯ã¡ã¿ã³ããšã¿ãã³åç¬æäžã®å Žåãããã¯ã¡ã¿
ã³ããšã¿ãã³ãšDLâãšãªã¹ãâDOPSãåææ
äžããå Žåãè¡šããã第ïŒå³ã¯ãã©ããŒã«ããã
ã³æäžããŠã¹ã®èªçºéåéã«ãããŒãDLâãšãª
ã¹ãâDOPSã®åœ±é¿ãã¿ããã®ã§ããã瞊軞ã¯èª
çºéåéãè¡šããã暪軞ã¯æéçµéïŒåïŒãè¡šã
ããç¢å°ã¯æè¬æéãè¡šããã
Claims (1)
- ïŒ ïŒ¬ãŸãã¯DLâãšãªã¹ãâïŒâïŒïŒïŒïŒâãžã
ãããã·ããšãã«ïŒâã»ãªã³ãŸãã¯ãã®å¡©ãæå¹
æåãšãã粟ç¥éåè奮æå¶å€ã
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58175581A JPS6067420A (ja) | 1983-09-22 | 1983-09-22 | 粟ç¥éåè奮æå¶å€ |
CA000452844A CA1225598A (en) | 1983-09-22 | 1984-04-26 | Pharmaceutical composition and method for treatment of psychomotor excitement |
US06/604,965 US4529603A (en) | 1983-09-22 | 1984-04-27 | Pharmaceutical composition and method for treatment of psychomotor excitement |
NZ20951484A NZ209514A (en) | 1983-09-22 | 1984-09-12 | Pharmaceutical compositions containing erythro-3,4-dihydroxyphenylserine and a decarboxylase inhibitor |
FR8414040A FR2552327B1 (fr) | 1983-09-22 | 1984-09-13 | Composition pharmaceutique a base de (dihydroxyphenyl)-serine et d'un inhibiteur de decarboxylase |
DE19843433675 DE3433675A1 (de) | 1983-09-22 | 1984-09-13 | Mittel zur behandlung von psychomotorischen erregungszustaenden |
NL8402850A NL8402850A (nl) | 1983-09-22 | 1984-09-17 | Werkwijze voor de behandeling van psychomotorische spanning, middel voor een dergelijke behandeling, alsmede farmaceutisch preparaat voor een dergelijke behandeling. |
IT8422685A IT8422685A0 (it) | 1983-09-22 | 1984-09-17 | Composizione farmaceutica eprocedimento per il trattamento di eccetazione psicomotoria. |
IT2268584A IT1175863B (it) | 1983-09-22 | 1984-09-17 | Composizione farmaceutica di ecctazione psicomotoria |
GB08423725A GB2146899B (en) | 1983-09-22 | 1984-09-19 | Treatment of psychomotor excitement |
SE8404715A SE468882B (sv) | 1983-09-22 | 1984-09-20 | Anvaendning av erytro-dops foer framstaellning av ett laekemedel foer behandling av psykomotorisk roerelse |
CH454184A CH664493A5 (de) | 1983-09-22 | 1984-09-21 | Mittel zur behandlung von psychomotorischen erregungszustaenden. |
BE6/48009A BE900654A (fr) | 1983-09-22 | 1984-09-21 | Composition pharmaceutique et procede de traitement de l'excitation. |
MX841284A MX167915B (es) | 1983-09-22 | 1984-09-24 | Procedimiento para preprar una composicion farmaceutica para el tratamiento de excitacion psicomotriz |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58175581A JPS6067420A (ja) | 1983-09-22 | 1983-09-22 | 粟ç¥éåè奮æå¶å€ |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6067420A JPS6067420A (ja) | 1985-04-17 |
JPH0331166B2 true JPH0331166B2 (ja) | 1991-05-02 |
Family
ID=15998583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58175581A Granted JPS6067420A (ja) | 1983-09-22 | 1983-09-22 | 粟ç¥éåè奮æå¶å€ |
Country Status (3)
Country | Link |
---|---|
US (1) | US4529603A (ja) |
JP (1) | JPS6067420A (ja) |
CA (1) | CA1225598A (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6185318A (ja) * | 1984-10-04 | 1986-04-30 | Sumitomo Seiyaku Kk | å©å°¿è¬ |
JPS62106015A (ja) * | 1985-10-31 | 1987-05-16 | Sumitomo Pharmaceut Co Ltd | æçŽåè¬ |
US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
US4983400A (en) * | 1986-06-16 | 1991-01-08 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
ZA889189B (en) * | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
JP3559572B2 (ja) * | 1993-01-29 | 2004-09-02 | äœå補è¬æ ªåŒäŒç€Ÿ | æ¥æ§çããã³æ ¢æ§ççšé®çå€ |
US8158149B2 (en) * | 2004-05-12 | 2012-04-17 | Chelsea Therapeutics, Inc. | Threo-DOPS controlled release formulation |
WO2004100929A1 (en) | 2003-05-12 | 2004-11-25 | Synergia Pharma, Inc. | Threo-dops controlled release formulation |
WO2005025561A1 (en) * | 2003-09-04 | 2005-03-24 | Synergia Pharma, Inc. | Compositions and methods for orthostatic intolerance |
PT1948155E (pt) * | 2006-06-28 | 2012-06-15 | Chelsea Therapeutics Inc | Composições farmacêuticas contendo droxidopa |
ES2480966T3 (es) * | 2007-03-09 | 2014-07-29 | Chelsea Therapeutics, Inc. | Droxidopa y composición farmacéutica de la misma para el tratamiento de la fibromialgia |
NZ581707A (en) * | 2007-05-07 | 2011-05-27 | Chelsea Therapeutics Inc | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
JP5880913B2 (ja) | 2011-05-17 | 2016-03-09 | äžé äœå€ç° | ããŒãã³ãœã³ç ã®äœå¹¹çç¶ïŒå§¿å¢åå°ç°åžžïŒã®æ²»çå€ |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52125630A (en) * | 1976-04-14 | 1977-10-21 | Kyowa Hakko Kogyo Co Ltd | Antiperkinson drugs containing l-threo-3,4-dihydroxyphenylserine |
JPS5520747A (en) * | 1978-08-01 | 1980-02-14 | Sumitomo Chem Co Ltd | Antidepressant |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH580059A5 (ja) * | 1973-08-22 | 1976-09-30 | Hoffmann La Roche | |
US3920728A (en) * | 1973-08-22 | 1975-11-18 | Hoffmann La Roche | Separation and resolution of isomeric forms of 3-(3,4-dihydroxy-phenyl)-serine |
JPS56104815A (en) * | 1980-01-23 | 1981-08-20 | Sumitomo Chem Co Ltd | Remedy for peripheral orthostatic hypotension |
JPS5852219A (ja) * | 1981-09-22 | 1983-03-28 | Sumitomo Chem Co Ltd | ãâãã³ãœã³ç æ²»çå€ |
-
1983
- 1983-09-22 JP JP58175581A patent/JPS6067420A/ja active Granted
-
1984
- 1984-04-26 CA CA000452844A patent/CA1225598A/en not_active Expired
- 1984-04-27 US US06/604,965 patent/US4529603A/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52125630A (en) * | 1976-04-14 | 1977-10-21 | Kyowa Hakko Kogyo Co Ltd | Antiperkinson drugs containing l-threo-3,4-dihydroxyphenylserine |
JPS5520747A (en) * | 1978-08-01 | 1980-02-14 | Sumitomo Chem Co Ltd | Antidepressant |
Also Published As
Publication number | Publication date |
---|---|
JPS6067420A (ja) | 1985-04-17 |
CA1225598A (en) | 1987-08-18 |
US4529603A (en) | 1985-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2395462T3 (es) | Inhibidores selectivos de la recaptación de norepinefrina-serotonina para el tratamiento del sÃndrome de fibromialgia, sÃndrome de fatiga crónica y dolor | |
JP4925074B2 (ja) | ãã«ã¿ã¶ãã³ãšïŒçš®ä»¥äžã®éžæçã»ãããã³ååã蟌ã¿é»å®³å€ãšãå«ãå»è¬çµæç© | |
KR20100134032A (ko) | ì ë³ì ïœ1ïœâ ìì©ì²Ž ìëìœì ëí í¬ìœ ìì | |
US20040029941A1 (en) | Zonisamide use in obesity and eating disorders | |
JP2007517901A (ja) | äœéã®æžå°ã«äœçšããé®çå€åã³æ粟ç¥ç å€ã®çµæç© | |
JPH0331166B2 (ja) | ||
AU2004216452A1 (en) | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug | |
BG64972B1 (bg) | СÑеЎÑÑвП Ñ Ð°ÐœÑОЎепÑеÑОвМП ЎейÑÑвОе | |
MX2012011395A (es) | Metodos de mejoramiento de la calidad del sueño. | |
US20090018205A1 (en) | Methods for treatment of migraine and symptoms thereof | |
CA2443105C (en) | Functional role for cannabinoids in autonomic stability during sleep | |
LEÌAN et al. | Beneficial effects of serotonin precursors in postanoxic action myoclonus | |
WO2007047372A2 (en) | Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists | |
KR100567154B1 (ko) | ížëŒë§ëì íšì íë ìœì íì ë°°í©ë¬Œ | |
KR20120050473A (ko) | íììŽì± ì§í ë° ë€ë¥ž ì ê²œê³ ì§íì ìë íììì ì 겜-ìžì§ ë°/ëë ì 겜-ì ì ììì ê°ì íêž° ìí 4-ìë¯žë žíŒëŠ¬ëì ì©ë | |
KR100346883B1 (ko) | ë§ì±íìì±ë맥겜íìŠìì¹ë£ìì ì©í칎륎ëíŽì ë첎-íšì ìœì | |
US11007158B2 (en) | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | |
ES2250749T3 (es) | Uso de una composicion combinada que comprende propionil l-carnitina y otros farmacos para el tratamiento de la disfuncion erectil. | |
JP2002356445A (ja) | å€çºæ§ç¡¬åçïŒïœïœïŒãä»ã®è±é«çç¶ãªãã³ã«æ«æ¢¢ç¥çµé害ãç¹ã«æçã®ç¥çµé害ããã³ç³å°¿ç æ§ç¥çµé害ã®å€å€äœµçšæ²»ç | |
SK19332001A3 (sk) | PouÅŸitie antagonistov kortizolu v lieÄenà srdcového zlyhania | |
Grundfast | A review of the efficacy of systemically administered decongestants in the prevention and treatment of otitis media | |
WO2007047576A1 (en) | Pharmacological treatments for sleep disorders | |
KR100573010B1 (ko) | ìŒíì 늰 ë° ïœ-칎륎ëíŽ ëë ìì¹Žë žìŒ ïœ-칎륎ëíŽìíšì íë ïœïœïœïœ ì¹ë£ì© ì¡°ì±ë¬Œ | |
TWI752282B (zh) | è¯ç²é žæå ¶é¹œåè¡çç©çšæŒé é²ææ²»çæ鬱çä¹çšé | |
Adams | Adrenergic agonists and antagonists |